Multibagger Pharma Stock Morepen Laboratories Surges 95% in a Month and Announces ₹0.20 Dividend

• by Akanksha Mishra
• 2026-09-02 16:35:00

Wealth creation in the pharmaceutical sector continues to grab investor attention as strong market momentum meets rewarding corporate payouts. Prominent pharmaceutical firm Morepen Laboratories has made headlines by officially announcing its upcoming corporate milestones, alongside a rewarding dividend payout for eligible shareholders. Riding on a wave of phenomenal capital appreciation, the company has declared a final dividend for the financial year 2025-26 while confirming the vital timeline for its upcoming annual shareholder gathering.

Dividend Details and Key Dates Announced

According to regulatory filings, the board of directors of Morepen Laboratories has recommended a final dividend of ₹0.20 per equity share having a face value for the financial year 2025-26. However, the final disbursement of this dividend remains subject to formal approval by shareholders at the company's upcoming 41st Annual General Meeting (AGM).

To determine shareholder eligibility for the payout, the company has established Saturday, September 19, 2026, as the official record date. Furthermore, the 41st AGM has been formally scheduled for Saturday, September 26, 2026. Management has urged investors to ensure their KYC details and bank mandates are updated with depository participants to facilitate seamless, direct electronic transfer of dividend funds upon approval.

Exceptional Price Performance and Multibagger Rally

Beyond the corporate payout, Morepen Laboratories has captured the market's imagination through an extraordinary surge in its share price. Currently trading around the ₹112 price band, the pharmaceutical counter has delivered stellar multi-fold returns across various time frames. The stock has posted a solid 16.25 percent gain over the past week alone, while registering a blistering rally of roughly 95 to 97 percent over the course of a single month. Looking at a broader horizon, the stock has skyrocketed an impressive 174.24 percent on a year-to-date basis, alongside a robust 132.41 percent return over the past twelve months.

Strong Fundamentals Driving Growth

Morepen Laboratories Limited maintains a robust operational presence across key segments of the healthcare sector, specializing in the manufacturing, development, and marketing of a diverse portfolio. Its core business lines encompass active pharmaceutical ingredients (APIs), high-quality branded and generic formulations, as well as a popular suite of home health products. With surging financial performance mirroring its impressive market rally, the company remains firmly positioned on investors' radar as both a growth and income-generating asset.

Previous Post

Safe, Secure, and Guaranteed: Why Post Office RD is Toppling Market Investments in 2026

Next Post

China Ends 30-Year Tax Exemption for Foreign Investors: New 20% Dividend Tax Takes Effect